Low eligibility for hepatitis B treatment in the Brazilian public health system

被引:1
|
作者
Oliveira Scarponi, Cristiane Faria [1 ]
Ferreira Pedrosa, Marco Antonio [2 ]
Gomes Mol, Marcos Paulo [3 ]
Mascarenhas Hardman, Michael John [4 ]
Greco, Dirceu Bartolomeu [5 ]
机构
[1] Fundacao Ezequiel Dias, Div Epidemiol & Controle Doencas, Belo Horizonte, MG, Brazil
[2] GeOpem Engn & Tecnol Ltd, Brejo Santo, CE, Brazil
[3] Fundacao Ezequiel Dias, Div Ciencia & Inovacao, Belo Horizonte, MG, Brazil
[4] Frimley Hlth NHS Fdn Trust, Frimley Pk Hosp, Camberley, Surrey, England
[5] Univ Fed Minas Gerais, Programa Posgrad Ciencia Saude Infectol & Med Tro, Belo Horizonte, MG, Brazil
关键词
Hepatitis B; Treatment eligibility; Guideline adherence; Antiviral therapy; Public health; Brazil; PRACTICE GUIDELINES; PRIMARY-CARE; MANAGEMENT; NATIONWIDE; STATEMENT; DISEASE; CANCER; FRANCE;
D O I
10.1590/0037-8682-0297-2021
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Background: Chronic hepatitis B (CHB) affects 257 million people worldwide. However, the proportion of patients eligible for treatment in the public health system has not been established. This study describes the clinical and laboratory profiles of untreated CHB patients and estimates the eligibility rate for antiviral therapy in accordance with the Brazilian Clinical Protocol and Therapeutic Guidelines. Methods: Records of 670 CHB patients were collected from May 2012 to September 2013 in Minas Gerais. Data from each patient were analyzed by hepatitis B virus (HBV) management. Results: 461 CHB patients were treatment-naive. Of these, 23 were HBeAg-positive, 352 were HBeAg-negative, and 14 were clinically diagnosed with cirrhosis. Periodic monitoring was performed in only three patients. However, 9.3% of untreated patients met the eligibility criteria for HBV treatment. Conclusions: Few CHB patients were active carriers and eligible candidates for antiviral therapy. This study revealed inadequate pretreatment conduct in the Brazilian public health system, emphasizing the need for regular laboratory follow-up for patients initially not eligible for treatment. Such information may indirectly subsidize the planning and improvement of actions and services related to optimal HBV management in the public sphere.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Estimated Costs of Clinical and Surgical Treatment of Severe Obesity in the Brazilian Public Health System
    Paula Rosales Zubiaurre
    Luciana Ribeiro Bahia
    Michelle Quarti Machado da Rosa
    Roberto Pereira Assumpção
    Alexandre Vontobel Padoin
    Samanta Pereira Sussembach
    Everton Nunes da Silva
    Claudio Corá Mottin
    Obesity Surgery, 2017, 27 : 3273 - 3280
  • [32] The BREATH Study: The Brazilian Experimental Algorithms for the Treatment of bipolar disorders in the public Health system
    Shansls, F. M.
    Lima, A. F. B.
    Gimeno, L.
    Oilveira, A. L.
    Olderich, V.
    Barcellos, A.
    Magalhaes, L.
    Marostica, L.
    BIPOLAR DISORDERS, 2010, 12 : 50 - 50
  • [33] Persistence associated with the use of biologicals for the treatment of ankylosing spondylitis in the Brazilian public health system
    dos Santos A. Santos, Barbara Rodrigues Alvernaz
    Oliveira, Gerusa A.
    Morgado, Marina
    Brandao, Natalia Dias
    Guerra Junior, Augusto Afonso
    Alvares-Teodoro, Juliana
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 170 - 170
  • [34] Estimated Costs of Clinical and Surgical Treatment of Severe Obesity in the Brazilian Public Health System
    Zubiaurre, Paula Rosales
    Bahia, Luciana Ribeiro
    Machado da Rosa, Michelle Quarti
    Assumpcao, Roberto Pereira
    Padoin, Alexandre Vontobel
    Sussembach, Samanta Pereira
    da Silva, Everton Nunes
    Mottin, Claudio Cora
    OBESITY SURGERY, 2017, 27 (12) : 3273 - 3280
  • [35] MEDICATION TREATMENT PATTERNS FOR MULTIPLE SCLEROSIS PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM
    Takemoto, M. M. S.
    Takemoto, M. L.
    Fernandes, R. A.
    Duarte, G. G. F.
    Moretti, A. I. P.
    Santos, P. M. L.
    Tolentino, A. C. M.
    VALUE IN HEALTH, 2011, 14 (03) : A212 - A213
  • [36] The treatment of diabetic macular edema with intravitreal bevacizumab in users of the Brazilian public health system
    Ibrahim, Larissa Fouad
    Soares, Aleida Nazareth
    Costa, Lucas Assis
    Domingues, Thabata Machado Correia
    Souza, Alessandra Hubner de
    ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2024, 87 (05)
  • [37] Patent Eligibility Reform and the Public Health
    Sherkow, Jacob S.
    MILBANK QUARTERLY, 2019, 97 (03): : 654 - 658
  • [38] A Novel and Simplified Score for Determining Treatment Eligibility for Patients with Chronic Hepatitis B
    Geeratragool, Tanawat
    Tangkijvanich, Pisit
    Nimanong, Supot
    Chainuvati, Siwaporn
    Charatcharoenwitthaya, Phunchai
    Tanwandee, Tawesak
    Chotiyaputta, Watcharasak
    VIRUSES-BASEL, 2023, 15 (03):
  • [39] Prevalence rates and eligibility for antiviral treatment against hepatitis B in Casamance, Senegal
    Arendt, Victor
    Thioubou, Mame Aisse
    Diallo, Kalilou
    Goedertz, Henri
    Diouf, Daouda
    Sambou, Benjamin
    Bindia, Chabi
    Cisse, Ousseynou
    Camara, Salimata
    Manga, Noel
    LassoDelaVeiga, Esther Calvo
    Diouf, Boubacar
    JOURNAL OF HEPATOLOGY, 2022, 77 : S304 - S304
  • [40] ASSESSMENT AND VALIDATION OF THE TREAT-B SCORE FOR CHRONIC HEPATITIS B VIRUS TREATMENT ELIGIBILITY
    Thanapirom, Kessarin
    Suksawatamnuay, Sirinporn
    Thaimai, Panarat
    Mungnamtrakul, Nawakodchamon
    Treeprasertsuk, Sombat
    Komolmit, Piyawat
    Tangkijvanich, Pisit
    GASTROENTEROLOGY, 2022, 162 (07) : S15 - S15